Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Accumulated Expenses (2016 - 2025)

Arcadia Biosciences' Other Accumulated Expenses history spans 12 years, with the latest figure at $270000.0 for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses rose 260.0% year-over-year to $270000.0; the TTM value through Mar 2025 reached $270000.0, up 260.0%, while the annual FY2024 figure was $172000.0, 290.91% up from the prior year.
  • Other Accumulated Expenses reached $270000.0 in Q1 2025 per RKDA's latest filing, up from $172000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $298000.0 in Q4 2022 to a low of $30000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $196470.6, with a median of $264000.0 recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 85.23% in 2023, then soared 290.91% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $162000.0 in 2021, then skyrocketed by 83.95% to $298000.0 in 2022, then crashed by 85.23% to $44000.0 in 2023, then skyrocketed by 290.91% to $172000.0 in 2024, then skyrocketed by 56.98% to $270000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Other Accumulated Expenses are $270000.0 (Q1 2025), $172000.0 (Q4 2024), and $30000.0 (Q3 2024).